Cypherpunk Technologies (CYPH) Stock Price, News & Analysis

Company Overview

Cypherpunk Technologies Inc., previously known as Leap Therapeutics, Inc., is a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The company’s research platform centers on modulating the tumor microenvironment to enhance anti-tumor immune responses. Cypherpunk’s proprietary pipeline includes DKN-01, a monoclonal antibody designed to neutralize Dickkopf-1 (DKK1), a protein implicated in tumor growth and immune evasion.

DKN-01 is being evaluated both as a monotherapy and in combination with checkpoint inhibitors such as pembrolizumab across multiple solid tumor indications, including gastroesophageal, pancreatic and other advanced malignancies. In addition to DKN-01, Cypherpunk is advancing preclinical programs that target novel pathways involved in cancer cell signaling and immune regulation, with the aim of identifying complementary assets for future clinical development.

Founded in 2016 and headquartered in Irvine, California, Leap Therapeutics completed its initial public offering in 2019 and now trades on the NASDAQ under the ticker CYPH. The company conducts clinical trials in the United States and collaborates with academic and industry partners to accelerate its development programs. Michael Stoll, M.D., serves as President and Chief Executive Officer, overseeing a team of experienced professionals in oncology drug discovery and development.

Key Stats

• Today's Range: $0.99 to $1.12
• 50-Day Range: $0.51 to $1.07
• 52-Week Range: $0.23 to $3.70
• Volume: 5.95 million shs
• Average Volume: 2.69 million shs
• Market Capitalization: $104.52 million
• P/E Ratio: 15.29
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Cypherpunk Technologies Stock Analysis - MarketRank™

Cypherpunk Technologies scored higher than 17% of companies evaluated by MarketBeat, and ranked 790th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Cypherpunk Technologies has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Cypherpunk Technologies has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Cypherpunk Technologies is 15.29, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 42.17.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cypherpunk Technologies is 15.29, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 24.91.

Price to Book Value per Share Ratio

Cypherpunk Technologies has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CYPH.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cypherpunk Technologies does not currently pay a dividend.

Dividend Growth

Cypherpunk Technologies does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: N/A

News Sentiment

Cypherpunk Technologies has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Cypherpunk Technologies this week, compared to 2 articles on an average week.

Search Interest

4 people have searched for CYPH on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cypherpunk Technologies insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.30% of the stock of Cypherpunk Technologies is held by insiders.

Percentage Held by Institutions

30.46% of the stock of Cypherpunk Technologies is held by institutions.

CYPH Stock Analysis - Frequently Asked Questions

How have CYPH shares performed this year?

Cypherpunk Technologies' stock was trading at $1.16 at the beginning of 2026. Since then, CYPH shares have decreased by 7.8% and is now trading at $1.07.

How were Cypherpunk Technologies' earnings last quarter?

Cypherpunk Technologies (NASDAQ:CYPH) released its quarterly earnings results on Wednesday, November, 12th. The company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.24) by $0.16. The company had revenue of $0.21 million for the quarter.

When did Cypherpunk Technologies' stock split?

Shares of Cypherpunk Technologies reverse split on the morning of Wednesday, June 21st 2023.The 1-10 reverse split was announced on Wednesday, June 21st 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Cypherpunk Technologies?

Shares of CYPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 11/12/2025
• Today: 5/05/2026
• Next Earnings (Estimated): 5/18/2026
• AGM 2026: 6/18/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CYPH
• Previous Symbol: NASDAQ:LPTX
• CIK: 1509745
• Web: www.leaptx.com
• Phone: (617) 714-0360
• Fax: N/A
• Employees: 40
• Year Founded: 2011

Profitability

• EPS (Trailing Twelve Months): $0.07
• Trailing P/E Ratio: 15.29
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $4.82 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -99.76%
• Return on Assets: -79.44%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 35.56
• Quick Ratio: 35.56

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.83 per share
• Price / Book: 0.58

Miscellaneous

• Outstanding Shares: 97,680,000
• Free Float: 86,111,000
• Market Cap: $104.52 million
• Optionable: Optionable
• Beta: -0.09